Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
This study is currently recruiting participants.
Verified March 2013 by Case Comprehensive Cancer Center
Sponsor:
Case Comprehensive Cancer Center
Collaborator:
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00899132
First received: May 9, 2009
Last updated: March 18, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.
| Condition | Intervention |
|---|---|
|
Non-melanomatous Skin Cancer Pancreatic Cancer Small Intestine Cancer Testicular Germ Cell Tumor |
Genetic: in situ hybridization Genetic: protein expression analysis Other: immunologic technique |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | The Role of TAB3 Protein in Tumorigenesis |
Resource links provided by NLM:
MedlinePlus related topics:
Cancer
Intestinal Cancer
Pancreatic Cancer
Skin Cancer
Testicular Cancer
U.S. FDA Resources
Further study details as provided by Case Comprehensive Cancer Center:
Primary Outcome Measures:
- Identification of TAB3 transcript/protein as a molecular marker of cancer [ Time Frame: end of study ] [ Designated as safety issue: No ]
- Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [ Time Frame: end of study ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Tumor tissue samples from paraffin-embedded tissue blocks.
| Estimated Enrollment: | 150 |
| Study Start Date: | February 2007 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Genetic: in situ hybridization
Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
Genetic: protein expression analysis
Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
Other: immunologic technique
Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
OBJECTIVES:
- To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.
- To characterize TAB3 and its signaling networks that are involved in tumorigenesis.
OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Primary care center
Criteria
DISEASE CHARACTERISTICS:
- Paraffin tissue blocks from surgical pathology cancer cases, specifically testicular, skin, small intestine, and pancreatic cancer, available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899132
Locations
| United States, Ohio | |
| Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center | Recruiting |
| Cleveland, Ohio, United States, 44106-5065 | |
| Contact: Clinical Trials Office - Case Comprehensive Cancer Center 800-641-2422 | |
Sponsors and Collaborators
Case Comprehensive Cancer Center
Investigators
| Study Chair: | Ge Jin, PhD | Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Case Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00899132 History of Changes |
| Other Study ID Numbers: | CASE5Y06, P30CA043703, CASE5Y06, CASE-5Y06-CC191 |
| Study First Received: | May 9, 2009 |
| Last Updated: | March 18, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Case Comprehensive Cancer Center:
|
skin cancer small intestine cancer pancreatic cancer malignant testicular germ cell tumor testicular teratoma |
Additional relevant MeSH terms:
|
Skin Neoplasms Pancreatic Neoplasms Testicular Neoplasms Duodenal Neoplasms Ileal Neoplasms Jejunal Neoplasms Neoplasms, Germ Cell and Embryonal Intestinal Neoplasms Neoplasms by Site Neoplasms Skin Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Digestive System Diseases |
Pancreatic Diseases Endocrine System Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Testicular Diseases Gonadal Disorders Gastrointestinal Neoplasms Gastrointestinal Diseases Duodenal Diseases Intestinal Diseases Ileal Diseases Jejunal Diseases Neoplasms by Histologic Type |
ClinicalTrials.gov processed this record on June 13, 2013